Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

NICE backs self-testing devices for patients at risk from blood clots


The number of heart attacks and strokes caused by blood clots could be reduced if patients were offered the chance to monitor themselves at home, according to the National Institute for Health and Care Excellence.

Latest NICE guidance said that some people at a higher risk of developing blood clots could benefit from being given diagnostic tools to test themselves.

The institute has recommended that clinicains should provide some patients with atrial fibrillation or heart valve disease, who are thought to be at high risk of developing blood clots, with monitoring devices which help patients to assess themselves.

The devices – the Coaguchek XS system made by Roche Diagnostics and the InRatio2 PT/INR Monitor made by Alere – can tell a patient how quickly blood clots and can let them know if they need to adjust their anti-blood clotting medication, such as warfarin.

Patients can either self test, where they monitor themselves and contact a health worker with the results who will advise on whether or not they need to change their dose, or self manage – where patients test themselves and then adjust their medication according to pre-agreed care protocol.

“Greater use of self-monitoring offers clinical and patient benefit”

Carole Longson

“The evidence shows that greater use of self-monitoring offers clinical and patient benefit and, over time, is likely to result in reductions in heart attacks and strokes caused by blood clots,” said Professor Carole Longson, director of the Health Technology Evaluation Centre at NICE.

Professor Carole Longson

Professor Carole Longson

“The time and cost of attending an anticoagulation clinic can be a significant burden for people on long-term oral anticoagulation therapy and can significantly affect both their working and family life,” she said.

“Because self-monitoring provides almost instant results, self-monitoring can reduce anxiety, provide a sense of control for the patient and remove the need to frequently attend clinics or hospitals,” she added.



Readers' comments (3)

  • michael stone

    Diabetics monitor their own blood-sugar levels, so why not also with patients who are at risk of blood clotting ?

    Although using anti-clotting drugs with a wider [safe] therapeutic window than some of the older drugs, would help for self-management, I suspect ?

    Unsuitable or offensive? Report this comment

  • In a word, Cost. Unless the price has come down significantly, these devices cost thousands. Same reason you don't see them on wards.

    Also with the rise of the new anticoagulant agents (that don't require monitoring and dose adjustment) it is quite likely warfarin will be phased out eventually.

    Unsuitable or offensive? Report this comment

  • michael stone

    Hi Charlie.

    Yep, 'cost' is frequently the reason.

    Unsuitable or offensive? Report this comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs